Back to Journals » Cancer Management and Research » Volume 11

Identification of potential key genes associated with ovarian clear cell carcinoma [Retraction]

Authors Xu Y, Shen K

Received 15 April 2019

Accepted for publication 15 April 2019

Published 26 April 2019 Volume 2019:11 Pages 3621—3622

DOI https://doi.org/10.2147/CMAR.S212312



Xu Y, Shen K. Identification of potential key genes associated with ovarian clear cell carcinoma. Cancer Management and Research. 018:10;5461–5470.

At the request of the author, the Editor-in-Chief and Publisher of Cancer Management and Research wish to retract the published article.

On review of their data the authors noted the western blot images shown in Figure 5A for proteins EPCAM and GATA6 of the published article were double banded. In published articles describing similar experimental conditions for EPCAM and GATA6 protein levels the authors observed the reported western blot bands were always only single banded. To investigate, the authors repeated the western blot experiments several
times and while they were able to report single bands for EPCAM and GATA6 proteins, they were unable to reproduce the same results described in the published article. As the conclusions of the article can no longer be supported the authors wish to retract their article.


Our decision-making was informed by our policy on publishing ethics and integrity and COPE’s retraction guidelines. The authors wish to apologize for this error.

This retraction relates to this paper

Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.